VCTX210
Phase 1- Indications
- Type 1 diabetes
Company intelligence / Profile preview
ViaCyte, Inc.
San Diego, California, United Statesinvestors.vrtx.com ↗
- Ownership
- Private
- Employees
- ~200
- Development stage
- Phase 2
01
Overview
ViaCyte developed stem cell-derived pancreatic endoderm cells that mature after transplantation and function to regulate blood glucose in rodent models. Their lead candidates included PEC-Direct and PEC-Encap for type 1 diabetes, with PEC-Direct being evaluated in Phase 1/2 trials before acquisition.
- Therapeutic areas
- Endocrinology
- Modalities
- Stem cell therapyCell replacement therapy
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
CRISPR TherapeuticsW.L. Gore & Associates
Beyond the preview
Go deeper on ViaCyte, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ViaCyte, Inc..